A homogeneous 384-well high-throughput binding assay for a TNF receptor using alphascreen technology

被引:18
作者
Wilson, J
Rossi, CP
Carboni, S
Fremaux, C
Perrin, D
Soto, C
Kosco-Vilbois, M
Scheer, A
机构
[1] Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland
[2] Serono Int SA, CH-1202 Geneva, Switzerland
[3] NovImmune SA, CH-1211 Geneva, Switzerland
关键词
alphascreen technology; protein-protein interaction; TNF receptor superfamily; high-throughput binding assay;
D O I
10.1177/1087057103257804
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
To take advantage of the growing knowledge of cellular signaling pathways, modern-day drug discovery faces an increasing challenge to develop assays to screen for compounds that modulate protein-protein interactions. One bottleneck in achieving this goal is a lack of suitable and robust assay technologies amenable to a high-throughput format. In this report, we describe how we utilized Alphascreen(TM) technology to develop a high-throughput assay to monitor ligand binding to a member of the tumor necrosis factor receptor superfamily. We expressed a fusion protein consisting of the extracellular domain of the OX40 receptor with the constant domains of human IgG. In the presence of OX40 ligand, we determined a binding affinity constant consistent with reported values and optimized the protocol to develop a simple, homogeneous, and sensitive binding assay in a 384-well format. Finally, we assessed if this system could identify small peptides capable of inhibiting the OX40 receptor and ligand interaction. The results showed that the assay was able to detect such peptides and could be used to launch a high-throughput screening campaign for small molecules able to prevent OX40 receptor activation. (Journal of Biomolecular Screening 2003:522-532)
引用
收藏
页码:522 / 532
页数:11
相关论文
共 40 条
[1]   Affinity and kinetics of the interaction between soluble trimeric OX40 ligand, a member of the tumor necrosis factor superfamily, and its receptor OX40 on activated T cells [J].
AlShamkhani, A ;
Mallett, S ;
Brown, MH ;
James, W ;
Barclay, AN .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (08) :5275-5282
[2]   A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity [J].
Baba, M ;
Nishimura, O ;
Kanzaki, N ;
Okamoto, M ;
Sawada, H ;
Iizawa, Y ;
Shiraishi, M ;
Aramaki, Y ;
Okonogi, K ;
Ogawa, Y ;
Meguro, K ;
Fujino, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (10) :5698-5703
[3]   The use of resonance energy transfer in high-throughput screening: BRET versus FRET [J].
Boute, N ;
Jockers, R ;
Issad, T .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2002, 23 (08) :351-354
[4]  
Brugnoni D, 1998, BRIT J RHEUMATOL, V37, P584
[5]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[6]   Antagonists of protein-protein interactions [J].
Cochran, AG .
CHEMISTRY & BIOLOGY, 2000, 7 (04) :R85-R94
[7]   UNDERSTANDING, IMPROVING AND USING GREEN FLUORESCENT PROTEINS [J].
CUBITT, AB ;
HEIM, R ;
ADAMS, SR ;
BOYD, AE ;
GROSS, LA ;
TSIEN, RY .
TRENDS IN BIOCHEMICAL SCIENCES, 1995, 20 (11) :448-455
[8]   Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL [J].
Degterev, A ;
Lugovskoy, A ;
Cardone, M ;
Mulley, B ;
Wagner, G ;
Mitchison, T ;
Yuan, JY .
NATURE CELL BIOLOGY, 2001, 3 (02) :173-182
[9]   Applications of novel resonance energy transfer techniques to study dynamic hormone receptor interactions in living cells [J].
Eidne, KA ;
Kroeger, KM ;
Hanyaloglu, AC .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2002, 13 (10) :415-421
[10]  
FORSTER T, 1948, ANN PHYS, V6, P54